NYSE:PRGO - Perrigo Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $44.82 -1.15 (-2.50 %) (As of 01/22/2019 02:14 PM ET)Previous Close$45.97Today's Range$44.37 - $45.4252-Week Range$36.28 - $95.93Volume632,569 shsAverage Volume2.07 million shsMarket Capitalization$6.25 billionP/E Ratio9.09Dividend Yield1.65%Beta1.1 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments. It offers OTC products in cough, cold, allergy, sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic, lifestyle, personal care and derma-therapeutics, natural health and vitamins, and anti-parasite categories. The company also develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. In addition, it offers contract manufacturing services. The company offers its products through retail drug, supermarket, and mass merchandise chains; hospitals; pharmacies; wholesalers; drug and grocery stores; and para pharmacies, as well as through a network of pharmacy sales force in North America, Europe, Australia, Israel, and China. Perrigo Company plc has a collaborative agreement with the Sol-Gel Technologies Ltd. for the development, manufacturing, and commercialization of an ivermectin cream in the United States. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. Receive PRGO News and Ratings via Email Sign-up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNYSE:PRGO Previous Symbol CUSIP71429010 Webwww.perrigo.com Phone353-1709-4000Debt Debt-to-Equity Ratio0.54 Current Ratio1.85 Quick Ratio1.26Price-To-Earnings Trailing P/E Ratio9.09 Forward P/E Ratio9.85 P/E Growth1.69 Sales & Book Value Annual Sales$4.95 billion Price / Sales1.23 Cash Flow$7.7948 per share Price / Cash Flow5.75 Book Value$43.81 per share Price / Book1.02Profitability EPS (Most Recent Fiscal Year)$4.93 Net Income$119.60 million Net Margins2.54% Return on Equity11.32% Return on Assets5.96%Miscellaneous Employees10,400 Outstanding Shares135,860,000Market Cap$6.25 billion OptionableOptionable Perrigo (NYSE:PRGO) Frequently Asked Questions What is Perrigo's stock symbol? Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO." How often does Perrigo pay dividends? What is the dividend yield for Perrigo? Perrigo announced a quarterly dividend on Wednesday, October 31st. Shareholders of record on Friday, November 30th will be given a dividend of $0.19 per share on Tuesday, December 18th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 1.70%. The ex-dividend date of this dividend is Thursday, November 29th. View Perrigo's Dividend History. How were Perrigo's earnings last quarter? Perrigo Company PLC (NYSE:PRGO) released its quarterly earnings data on Thursday, November, 8th. The company reported $1.09 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.05 by $0.04. The company earned $1.13 billion during the quarter, compared to analyst estimates of $1.17 billion. Perrigo had a net margin of 2.54% and a return on equity of 11.32%. The firm's quarterly revenue was down 8.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.39 earnings per share. View Perrigo's Earnings History. When is Perrigo's next earnings date? Perrigo is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Perrigo. What guidance has Perrigo issued on next quarter's earnings? Perrigo issued an update on its FY18 earnings guidance on Thursday, November, 8th. The company provided earnings per share (EPS) guidance of $4.45-4.65 for the period, compared to the Thomson Reuters consensus estimate of $4.86. The company issued revenue guidance of ~$4.72 billion, compared to the consensus revenue estimate of $4.87 billion.Perrigo also updated its FY 2018 guidance to $4.45-4.65 EPS. What price target have analysts set for PRGO? 13 Wall Street analysts have issued 1-year target prices for Perrigo's shares. Their predictions range from $46.00 to $110.00. On average, they anticipate Perrigo's share price to reach $77.3571 in the next twelve months. This suggests a possible upside of 72.6% from the stock's current price. View Analyst Price Targets for Perrigo. What is the consensus analysts' recommendation for Perrigo? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perrigo in the last year. There are currently 1 sell rating, 10 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Perrigo. Has Perrigo been receiving favorable news coverage? Media stories about PRGO stock have trended very positive on Tuesday, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Perrigo earned a news impact score of 3.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days. Are investors shorting Perrigo? Perrigo saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 5,474,515 shares, a decline of 37.7% from the December 14th total of 8,791,586 shares. Based on an average daily trading volume, of 3,537,573 shares, the short-interest ratio is currently 1.5 days. Currently, 4.0% of the shares of the stock are sold short. View Perrigo's Current Options Chain. Who are some of Perrigo's key competitors? Some companies that are related to Perrigo include Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Mylan (MYL), Ono Pharmaceutical (OPHLF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Genmab A/S (GNMSF), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Nektar Therapeutics (NKTR) and Ionis Pharmaceuticals (IONS). Who are Perrigo's key executives? Perrigo's management team includes the folowing people: Mr. Ronald L. Winowiecki, Chief Financial Officer (Age 53)Mr. Todd W. Kingma, Exec. VP, Gen. Counsel & Sec. (Age 59)Mr. Sharon Kohan, Exec. VP & Pres of Branded Consumer Healthcare and International (Age 51)Mr. Jeffrey R. Needham, Exec. VP & Pres of Consumer Healthcare Americas (Age 63)Mr. Murray S. Kessler, CEO, Pres & Director (Age 59) Who are Perrigo's major shareholders? Perrigo's stock is owned by a variety of of institutional and retail investors. Top institutional investors include GW Henssler & Associates Ltd. (0.05%), Nippon Life Global Investors Americas Inc. (0.03%), State of Alaska Department of Revenue (0.03%), Nisa Investment Advisors LLC (0.02%), Moon Capital Management LLC (0.02%) and Meeder Asset Management Inc. (0.02%). Company insiders that own Perrigo stock include Geoffrey M Parker, Jeffrey C Smith, Jeffrey Needham, John Wesolowski, Murray S Kessler, Sharon Kochan, Svend Andersen, Thomas Farrington, Todd W Kingma and Uwe Roehrhoff. View Institutional Ownership Trends for Perrigo. Which major investors are selling Perrigo stock? PRGO stock was sold by a variety of institutional investors in the last quarter, including Moon Capital Management LLC, GW Henssler & Associates Ltd. and Louisiana State Employees Retirement System. View Insider Buying and Selling for Perrigo. Which major investors are buying Perrigo stock? PRGO stock was purchased by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc., Nippon Life Global Investors Americas Inc., State of Alaska Department of Revenue and Nisa Investment Advisors LLC. Company insiders that have bought Perrigo stock in the last two years include Geoffrey M Parker, Jeffrey C Smith, John Wesolowski, Murray S Kessler, Svend Andersen, Todd W Kingma and Uwe Roehrhoff. View Insider Buying and Selling for Perrigo. How do I buy shares of Perrigo? Shares of PRGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Perrigo's stock price today? One share of PRGO stock can currently be purchased for approximately $44.82. How big of a company is Perrigo? Perrigo has a market capitalization of $6.25 billion and generates $4.95 billion in revenue each year. The company earns $119.60 million in net income (profit) each year or $4.93 on an earnings per share basis. Perrigo employs 10,400 workers across the globe. What is Perrigo's official website? The official website for Perrigo is http://www.perrigo.com. How can I contact Perrigo? Perrigo's mailing address is TREASURY BUILDING LOWER GRAND CANAL STREET, DUBLIN L2, 49010. The company can be reached via phone at 353-1709-4000 or via email at [email protected] MarketBeat Community Rating for Perrigo (NYSE PRGO)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 650 (Vote Outperform)Underperform Votes: 617 (Vote Underperform)Total Votes: 1,267MarketBeat's community ratings are surveys of what our community members think about Perrigo and other stocks. Vote "Outperform" if you believe PRGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRGO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/22/2019 by MarketBeat.com StaffFeatured Article: What is the quiet period?